HIV Disclosure, Condom Use, and Awareness of HIV Infection Among HIV-Positive, Heterosexual Drug Injectors in St. Petersburg, Russian Federation

Lauretta E. Grau · Edward White · Linda M. Niccolai · Olga V. Tousova · Sergei V. Verevochkin · Andrei P. Kozlov · Robert Heimer

Published online: 11 August 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com

Abstract We examined the prevalence of HIV disclosure to sexual partners by HIV-positive drug injectors (IDUs) in St. Petersburg, Russia and compared the magnitude and direction of associations of condom use with awareness of one’s HIV infection and disclosure to partners. Among 157 HIV-infected participants, awareness of infection at time of last intercourse was associated with condom use with partners perceived to be HIV-negative (aOR 6.68, 95% CI 1.60–27.88). Among the 70 participants aware of their infection prior to enrolment, disclosure to potentially uninfected sexual partners was independently and negatively associated with condom use (aOR 0.13, 95% CI 0.02–0.66). Disclosure was independently associated with having injected ≥9 years (aOR 6.04, 95% CI 1.53–23.77) and partnership with another IDU (aOR 3.61, 95% CI 1.44–9.06) or HIV-seropositive (aOR 45.12, 95% CI 2.79–730.46). Scaling up HIV testing services and interventions that increase the likelihood of individuals receiving their test results is recommended.

Keywords HIV disclosure · HIV testing · Condom use · Injection drug use · Russia

Introduction

Russia faces one of the most rapidly expanding AIDS epidemics [1, 2], with more than 470,000 registered HIV cases at the end of 2008 and the estimated number of infections exceeding one million [3, 4]. Thus far, the overwhelming majority of those infected are injection drug users (IDUs) [1, 2, 5–8]. Estimates of HIV seroprevalence among St. Petersburg IDUs indicate a rise from 2–4% in 1998 to 11–18% in 2000 to 30% in 2002 to 49% in 2008 [9–14]. There is also evidence that HIV is spreading to the general population via heterosexual contact [7, 15–17].

In the West and particularly in the US, recent HIV prevention efforts have focused on promoting HIV counseling and testing with disclosure of HIV serostatus to prospective sexual partners [18, 19]. Estimates of the proportions of HIV-infected heterosexuals in the West who disclose to partners range from 60 to 80% [20–22]. By contrast, the issue of disclosure and its potential public health impact is largely unexplored in Russia. Only limited anonymous HIV testing is available in Russia, and lack of access to treatment as well as the pervasive stigma associated with HIV disease [23, 24] often dissuade people from being tested. Although many Russians have been tested for HIV at least once in their lives, the testing most commonly occurs as a result of incarceration or an in-patient medical visit. Only approximately one in five IDUs who self-identify as HIV-negative had been tested within the previous year [25]. Since HIV testing is not as prevalent as in the West, the relationship between awareness of one’s HIV status, disclosure, and condom use is poorly understood. The current study is the first to examine these issues within a sample of IDUs in St. Petersburg, Russia.

In several US studies, disclosure appears to be influenced by contextual, temporal, and situational factors [26,
Individuals disclose to primary more than to non-primary or anonymous partners [22, 26–33]. Studies suggest that the spread of HIV may be fueled by a relatively small number of infected individuals who engage in multiple high-risk behaviors (e.g., multiple partners, unprotected sex) without disclosure [27, 34–36]. Partner characteristics also influence disclosure behavior such that disclosure was less likely to occur with younger partners [37] or with those whose serostatus is understood to be negative or to be unknown [28, 38–40]. Additionally, timing of disclosure (i.e., prior or subsequent to unprotected sex) is not clearly identified [27], and therefore, sex partners may underestimate their HIV risk [38, 41, 42]. People need time to adjust to their diagnosis—typically 2–3 years—after which time disclosure is more likely to occur [39, 43–45].

The few studies assessing HIV testing awareness in Russia or other countries of the former Soviet Union suggest that fewer than 40% of Russian participants were aware of their partner’s HIV status at time of sex [25, 46]. Pervasive stigma surrounding HIV in Russia [23, 24] may dissuade people from disclosing [47]. We are unaware of any scientific publications that specifically examine HIV disclosure behavior among Russian IDUs, although there is some evidence from Western Europe that IDUs’ awareness of their HIV infection was associated with increased condom use [48]. Since the epidemic is currently concentrated among IDUs, we began such explorations by seeking to identify individual and interpersonal factors that influence disclosure and condom use behaviors in this population. Specifically, we used data on recent sexual partnerships from HIV-infected IDUs, only some of whom had been aware of their infection at time of last intercourse to address four questions: (1) Among HIV-infected IDUs, is knowledge of their infection associated with increased condom use? (2) What individual, partner, and partnership characteristics are associated with disclosure by HIV-positive IDUs? (3) Is disclosure by HIV-positive IDUs associated with condom use? and (4) Is disclosure of positive status or awareness of positive status more strongly associated with condom use? This constitutes a first step in determining whether and the extent to which HIV disclosure should be emphasized in future prevention interventions for Russian IDUs.

Methods

As part of a larger multi-site, cross-sectional study, “Sexual Acquisition and Transmission of HIV - Cooperative Agreement Program” (SATH-CAP), data were collected in St. Petersburg from September 2005 to December 2008. SATH-CAP seeks to identify the structural, social, and individual factors associated with HIV risk behavior among high-risk populations, one of which is users of heroin, cocaine, or amphetamine-type stimulants, and the sex partners of these participants. Sampling and recruitment procedures, data collection instruments, and other study methods have been reported in detail elsewhere [25, 49]; specifics relevant to this study are described below.

Participants

Participants were recruited using a modified version of respondent-driven sampling (RDS) [49–51]. Previous analysis found less than 5% overlap between drug users and men who have sex with men (MSM) and greater than 95% prevalence of injection among the drug users [10, 25]. The present analysis is restricted to SATH-CAP participants who (1) were 18 years or older, (2) reported injecting illicit drugs at least once in their life, (3) tested positive for HIV infection as part of the SATH-CAP serological testing, and (4) supplied information about their sex partners within the past 6 months (Fig. 1). Participants were provided incentives equivalent to US$10 for their participation and US$5 for each person they successfully referred to the study. All study and consent procedures and study

Fig. 1 Derivation from the SATH-CAP cohort of the subsample used in the current analyses. We limited the analyses to those participants who reported ever having injected drugs and who tested positive for HIV infection at enrolment (n = 300). We first examined the association between prior knowledge of HIV status and condom use at last intercourse in each of their sexual partnerships. Subsequently, among participants who were aware of their HIV infection prior to enrolment, we examined the association between disclosure of HIV status to and condom use with their reported sex partners.
measures were approved by institutional review boards at The Biomedical Center, Yale University, and RAND Corporation.

Data Collection, Measures, and Laboratory Procedures

Participants completed a structured, computer-assisted, self-administered interview and, following pre-test HIV counseling, had blood drawn for serological testing. Data used in the present analyses included demographic, medical history, drug and sex behaviors, sex partner information, and HIV serology. Demographic variables included sex, age, marital status, living situation, educational level, current employment status, legal income (past 30 days), and history of incarceration. Medical history items included HIV testing history and whether participants had received their most recent test results. Participants reporting HIV infection were asked the month and year of their diagnosis. We define “HIV-seropositive” as seropositive test results based on the testing performed as part of this study and “previously aware of diagnosis” as participants who reported having been informed that they were HIV-positive prior to enrolling in this study. Drug use data included duration of injection drug use (median-split at 9 years), number of injections in past 30 days (median-split at 22), and unsafe injections in past 30 days (yes/no; defined as sharing needles without using bleach, using a single syringe to mix or divide drugs, or sharing cookers, cotton, or water). Sexual behavior data included number of sex partners in the prior 6 months, number of new partners in the past 6 months, partner-specific information (i.e., for main partner, up to three most recent non-main partners, and if applicable, a partner with whom they also shared drugs), and condom use at last sexual intercourse with up to five partners in the previous 6 months. Partner-specific data included each partner’s age and gender, partnership type (main vs. casual/friend vs. stranger/sex trade), disclosure of HIV status to partner, and perceived injection drug use history of partner. Perceived HIV status was ascertained by asking about each partner “What is [the partner’s] HIV status?” and were given as potential responses “I don’t know or am not sure”, “I am sure he/she is HIV negative” and “I am sure he/she is HIV-positive”. Participants who responded that a partner was positive were then asked “Do you know [the partner’s] HIV status because he/she told you him/herself?” Participants were also asked for each partner “Does [the partner] know your HIV status?” Those answering in the affirmative were then asked “Does [the partner] know your HIV status because you told him/her yourself?” We included all reported partnerships in these analyses except those in the previously aware of diagnosis group for whom the date of last intercourse occurred before they became aware of their HIV diagnosis.

Analytical Methods

Standard descriptive statistics were used to describe the sample. Continuous variables were dichotomized in order to adapt those with non-normal distributions to parametric tests and to preserve statistical power. Using Chi-square and Wilcoxon rank-sum tests, we compared the characteristics of seropositives who were aware of their HIV infection with those who were not, examined whether the demographic characteristics of participants who provided information on sexual partnerships differed from those who did not, and examined whether partner characteristics were associated with the participant’s perception of their partners’ serostatus. We employed population-averaged panel-data models to account for single participants’ ability to report on more than one partner. This was accomplished using generalized estimating equations (GEE), under the command—gee—in Stata 10 [52]. We used the same technique to assess among participants who were aware of their infection, whether any participant, partner, or partnership characteristic was associated with disclosure within the partnership.

Among partnerships reported by HIV-infected participants, we assessed bivariate associations between the participant’s awareness of being infected with HIV at the time of their last sexual encounter and condom use at that time. We assessed these associations within all reported partnerships and within a subset of partnerships with partners either perceived to be uninfected or of unknown serostatus. To estimate associations between awareness of infection and condom use, unconfounded by other available individual, partner, and partnership characteristics, we also assessed associations between condom use and participant’s age, duration of injection drug use, history of incarceration, partnership type, and participant’s understanding of whether partners also injected drugs and perceived serostatus of partners. In each case, covariates that were associated in bivariate analyses at P < 0.20 were entered into an initial multivariate model; backward selection eliminated covariates that did not remain significant at P < 0.05 or did not change other coefficients by >10%. This was done for all partnerships and the three aforementioned subsets.

We then limited analysis to participants who were aware of their HIV infection prior to study enrolment. Among partnerships reported by these participants, we assessed bivariate associations between participants’ disclosure of positive serostatus and condom use, and produced multivariate models in the manner described above for all reported partnerships and the three aforementioned subsets.

To account for potential confounders in any association between prior awareness of HIV infection and condom use, we identified associations between prior diagnosis of HIV infection and participant characteristics using Chi-square
or Fisher’s exact test; for non-normally distributed variables we used the Wilcoxon rank-sum test. For condom use, we calculated unadjusted and adjusted correlations between dependent and independent variables. In each case, covariates that were associated in bivariate analyses at \( P < 0.20 \) were entered into an initial multivariate model; backward selection eliminated covariates that did not remain significant at \( P < 0.05 \) or did not change other coefficients by \( >10\% \).

Participants could refer their sex partners to the study, raising the possibility of double-reporting of sex partnerships between two participants, once by the recruiter and once by the recruit. To account for potential correlation we nested responses by the participant who had referred the partner to the study. Therefore, partnerships reported with participants’ recruiters were excluded from analysis if both participant and recruiter were present in the subset of observations analyzed.

Because participants were recruited using RDS, use of weighting procedures was considered to adjust the sample for recruitment probabilities to obtain estimates that would reflect the underlying population from which sampling was conducted. However, in prior analyses of these data, proportions of demographic and serologic characteristics did not differ substantially between weighted and unweighted distributions. Therefore, we used unweighted estimates for these analyses [25].

**Results**

**Characteristics of the Study Sample**

Of 691 participants who reported a history of drug injection, 301 (44%) tested HIV-seropositive at the time of enrolment. Among these seropositive participants, 38 reported having no sex partners, 46 participants provided no data on the number of sex partners they had in the prior 6 months (therefore not asked partner-specific items), and 30 declined to provide partnership data. We also excluded from analysis ten males who reported sex with male partners only and 20 participants who reported sex partnership only with their recruiter. Thus, we restricted analyses to the 157 heterosexual, HIV-seropositive participants who provided data on 231 non-overlapping partnerships (Fig. 1). We found no significant demographic differences between participants who provided data partnership data and those who did not.

Nearly two-thirds of the resulting sample were male (65%). The median age was 28 years (25%, 75% = 24, 32 years), with approximately twice as many single participants as married/partnered participants. Most participants (69%) lived with either their families or friends. Over half (56%) had at least some post-secondary education. Few (37%) were currently employed; median income from legal sources was 1,625 rubles (US$50) in the last month (25%, 75% = 0, 7,000 rubles; data not shown). Fewer than half the participants (42%) reported ever having been incarcerated. The median duration of injection drug use was 9.2 years (25%, 75% = 6, 11; data not shown), and nearly all (92%) reported injecting within the prior 30 days. The median number of injections in the prior 30 days was 23 (25%, 75% = 10, 30; data not shown); the majority of participants (79%) reported injecting unsafely (e.g., sharing syringe, cooker, cotton, and/or water) at least once in the prior 30 days. In the previous 6 months, 61% reported having sex with a new partner, and 40% reported having more than one partner (Table 1).

Most participants (80%) reported having been tested for HIV at least once (Table 1), and of those tested, most (82%) reported having received their test results (data not shown). Less than half (45%) the sample reported having been aware of their HIV infection prior to enrolment. Of these, 73% had received their positive test results more than 2 years ago (data not shown); no date of diagnosis was available for 3 of the 70 participants who were previously aware of their HIV infection. No participant characteristic was significantly associated with prior diagnosis of HIV infection save marital status (\( \chi^2 = 6.64, \ P = 0.042 \); Table 1).

**Characteristics of Participants’ Reported Sex Partners**

Participants reported approximately one in five partners (19%) to be HIV-seropositive, with most partners (80%) communicating this information directly to the participant (data not shown). Of the partners perceived to be seronegative (31%), participants reported asking most (71%) whether they had been tested for HIV (data not shown). Of the partners whose serostatus was “unknown” to the participant (50%), fewer than a third (29%) had been asked by the participant whether they had been tested for HIV (data not shown). Participants were no more likely to report knowing the HIV status of their primary sex partners than of their other partners. Participants were more likely to perceive IDU partners as HIV-positive than as seronegative or of unknown serostatus (\( P < 0.001 \); data not shown). No other partner characteristic (e.g., partner’s gender, partner’s age, partnership type) was associated with perception of partner’s serostatus.

**Association Between Previous Awareness of HIV Diagnosis and Condom Use at Last Intercourse**

Participants reported using condoms at last intercourse in 115 (50%) of 231 partnerships (Table 2). Awareness of
one’s HIV infection was not associated with condom use in a model that included all partners regardless of participants’ perception of partner serostatus. Instead, participants were less likely to use condoms with their primary partners (aOR 0.60, 95% CI 0.38–0.96; \( P = 0.034 \)) and with IDU partners (aOR 0.39, 95% CI 0.23–0.66; \( P < 0.001 \)).

### Table 1

Characteristics of HIV seropositive drug injectors, by previous diagnosis of HIV infection, St. Petersburg, Russia (2005–2008) (\( n = 157 \) unless otherwise noted)

| Characteristic                                      | No. (%) diagnosed | No. (%) undiagnosed | Total | \( \chi^2 \) | \( P \) |
|-----------------------------------------------------|------------------|---------------------|-------|-------------|------|
| Total                                               | 70 (45)          | 87 (55)             | 157 (100) |             |      |
| Gender                                              |                  |                     |       |             |      |
| Male                                                | 44 (63)          | 58 (67)             | 102 (65) | 0.247       | 0.619|
| Female                                              | 26 (37)          | 29 (33)             | 55 (35)  |             |      |
| Age\(^a\)                                           | 28 (25, 32)      | 28 (24, 32)         | 28 (24, 32) | -0.540\(^d\) | 0.590|
| Marital status                                      |                  |                     |       |             |      |
| Married or partnered                                | 22 (31)          | 37 (43)             | 58 (38)  | 6.635       | 0.042|
| Single, divorced, widowed or separated              | 48 (69)          | 50 (57)             | 98 (62)  |             |      |
| Living situation                                    |                  |                     |       |             |      |
| Alone or with partner                               | 24 (34)          | 22 (25)             | 46 (29)  | 0.323\(^d\) | 0.315|
| With family or friends                             | 44 (63)          | 64 (74)             | 108 (69) |             |      |
| Shelter or SRO                                      | 2 (3)            | 1 (1)               | 3 (2)    |             |      |
| Postsecondary education                             |                  |                     |       |             |      |
| Yes                                                 | 39 (56)          | 49 (56)             | 88 (56)  | 0.006       | 0.939|
| No                                                  | 31 (44)          | 38 (44)             | 69 (44)  |             |      |
| Full/part-time employment                           |                  |                     |       |             |      |
| Yes                                                 | 26 (37)          | 32 (37)             | 58 (37)  | 0.002       | 0.963|
| No                                                  | 44 (63)          | 55 (65)             | 99 (63)  |             |      |
| Any legal income (past 30 days)                     |                  |                     |       |             |      |
| Yes                                                 | 44 (66)          | 48 (65)             | 90 (92)  | 0.009       | 0.926|
| No                                                  | 22 (34)          | 26 (35)             | 48 (35)  |             |      |
| Ever in jail or prison                              |                  |                     |       |             |      |
| Yes                                                 | 34 (49)          | 32 (37)             | 66 (42)  | 2.213       | 0.137|
| No                                                  | 36 (51)          | 55 (63)             | 91 (58)  |             |      |
| Ever tested for HIV                                 |                  |                     |       |             |      |
| Yes                                                 | 70 (100)         | 55 (63)             | 125 (80) | 32.338\(^d\) | <0.001|
| No                                                  | 0 (0)            | 32 (37)             | 32 (20)  |             |      |
| Injecting for past 9 years or longer                |                  |                     |       |             |      |
| Yes                                                 | 40 (57)          | 39 (45)             | 79 (50)  | 2.353       | 0.125|
| No                                                  | 30 (43)          | 48 (55)             | 78 (50)  |             |      |
| Injected last 30 days                               |                  |                     |       |             |      |
| Yes                                                 | 64 (94)          | 77 (91)             | 141 (92) | 0.550\(^d\) | 0.420|
| No                                                  | 4 (6)            | 8 (9)               | 12 (8)   |             |      |
| Injections/month > 22\(^b\)                         |                  |                     |       |             |      |
| Yes                                                 | 29 (45)          | 42 (55)             | 71 (50)  | 1.192       | 0.275|
| No                                                  | 35 (55)          | 35 (45)             | 70 (50)  |             |      |
| Unsafe injection 30 days\(^b\)                      |                  |                     |       |             |      |
| Yes                                                 | 52 (81)          | 60 (78)             | 112 (79) | 0.237       | 0.626|
| No                                                  | 12 (19)          | 17 (22)             | 29 (21)  |             |      |
| New sex partner, 6 months                           |                  |                     |       |             |      |
| Yes                                                 | 43 (61)          | 52 (60)             | 95 (61)  | 0.045       | 0.833|
| No                                                  | 27 (39)          | 35 (40)             | 62 (39)  |             |      |
| More than one sex partner, 6 months                 |                  |                     |       |             |      |
| Yes                                                 | 27 (39)          | 36 (41)             | 63 (40)  | 0.127       | 0.721|
| No                                                  | 43 (61)          | 51 (59)             | 94 (60)  |             |      |

\(^a\) Median (25th percentile, 75th percentile)

\(^b\) Excludes participants who did not report having injected in the past 30 days

\(^c\) Z-score for Wilcoxon rank-sum test

\(^d\) Fisher’s exact Chi-square
| Table 2 | Correlates of condom use at last sexual intercourse among drug injectors in St. Petersburg, Russia |
|---------|--------------------------------------------------------------------------------------------------|
| | Total | Used condom No. (%) | uOR | 95% CI | P-value | aOR | 95% CI | P-value |
| **With any partner n\textsubscript{participants} = 157** | | | | | | | | |
| Total partnerships | 231 | 115 (50) | – | – | – | – | – | – |
| Awareness of infection in positive injector | | | | | | | | |
| Yes | 106 | 52 (49) | 1.19 | 0.64–2.20 | 0.587 | | | |
| No | 125 | 63 (50) | Ref | | | | | |
| Gender | | | | | | | | |
| Male | 152 | 81 (53) | 1.52 | 0.80–2.90 | 0.207 | | | |
| Female | 79 | 34 (43) | Ref | | | | | |
| Age 28 plus | | | | | | | | |
| Yes | 121 | 64 (53) | 1.41 | 0.76–2.62 | 0.270 | | | |
| No | 110 | 51 (46) | Ref | | | | | |
| Inject 9 years | | | | | | | | |
| Yes | 115 | 63 (55) | 1.54 | 0.83–2.85 | 0.168 | | | |
| No | 116 | 52 (45) | Ref | | | | | |
| IDU’s perception of partner’s serostatus | | | | | | | | |
| Positive | 44 | 18 (41) | Ref | | | | | |
| Negative | 71 | 40 (56) | 1.79 | 0.87–3.71 | 0.114 | | | |
| Unknown | 115 | 57 (50) | 1.28 | 0.66–2.51 | 0.466 | | | |
| Partner type | | | | | | | | |
| Main | 104 | 50 (48) | 0.67 | 0.43–1.05 | 0.078 | 0.60 | 0.38–0.96 | 0.034 |
| Other | 100 | 61 (61) | Ref | | | | | |
| Partner injects drugs | | | | | | | | |
| Yes | 125 | 48 (38) | 0.36 | 0.23–0.58 | <0.001 | 0.39 | 0.23–0.66 | <0.001 |
| No | 95 | 50 (63) | Ref | | | | | |
| **With partners perceived to be seronegative n\textsubscript{participants} = 50** | | | | | | | | |
| Total partnerships | 71 | 40 (56) | – | – | – | – | – | – |
| Awareness of infection in positive injector | | | | | | | | |
| Yes | 27 | 19 (70) | 3.76 | 1.11–12.66 | 0.033 | 6.68 | 1.60–27.88 | 0.009 |
| No | 44 | 20 (48) | Ref | | | Ref | | |
| Gender | | | | | | | | |
| Male | 50 | 30 (60) | 1.75 | 0.55–5.52 | 0.344 | | | |
| Female | 21 | 10 (48) | Ref | | | | | |
| Age 28 plus | | | | | | | | |
| Yes | 33 | 20 (61) | 1.25 | 0.44–3.58 | 0.677 | | | |
| No | 38 | 20 (53) | Ref | | | | | |
| Inject 9 years | | | | | | | | |
| Yes | 34 | 21 (62) | 1.59 | 0.55–4.58 | 0.391 | | | |
| No | 37 | 19 (51) | Ref | | | | | |
| Partner type | | | | | | | | |
| Main | 38 | 19 (50) | 0.52 | 0.22–1.20 | 0.125 | | | |
| Other | 29 | 20 (69) | Ref | | | | | |
| Partner injects | | | | | | | | |
| Yes | 23 | 10 (43) | 0.42 | 0.17–1.06 | 0.060 | 0.29 | 0.11–0.74 | 0.009 |
| No | 48 | 30 (63) | Ref | | | | | |
separate model of partnerships limited to partners understood to be seronegative and adjusted for the strong negative correlation of condom use with partner’s injection drug use, participants’ awareness of their HIV infection was associated with condom use (aOR 6.68, 95% CI 1.60–27.88; \( P = 0.009 \)). In a model of partnerships with sex partners of unknown serostatus, participants who had been aware of their HIV infection at the time of sexual intercourse were no more likely to have used condoms than those who had been unaware. Similar to the findings for all partners, participants were less likely to use condoms with partners assumed to be an IDU (aOR 0.32, 95% CI 0.17–0.62; \( P = 0.001 \)).

Table 2 continued

| Total Used condom | uOR 95% CI | P-value | aOR 95% CI | P-value |
|-------------------|------------|---------|------------|---------|
| Total partnerships| 115        | 57 (50) | –          | –       |
| Awareness of infection in positive injector | | | | |
| Yes | 40 | 19 (48) | 1.01 | 0.41–2.46 | 0.989 |
| No | 75 | 38 (51) | Ref | | |
| Gender | | | | |
| Male | 77 | 40 (52) | 1.67 | 0.66–4.33 | 0.278 |
| Female | 38 | 17 (45) | Ref | | |
| Age 28 plus | | | | |
| Yes | 61 | 34 (55) | 1.91 | 0.79–4.58 | 0.150 |
| No | 54 | 23 (43) | Ref | | |
| Inject 9 years | | | | |
| Yes | 58 | 33 (57) | 1.86 | 0.78–4.43 | 0.162 |
| No | 57 | 24 (42) | Ref | | |
| Partner type | | | | |
| Main | 46 | 23 (50) | 0.76 | 0.38–1.49 | 0.419 |
| Other | 56 | 32 (57) | Ref | | |
| Partner injects | | | | |
| Yes | 65 | 25 (38) | 0.32 | 0.17–0.62 | 0.001 |
| No | 39 | 25 (64) | Ref | Ref | Ref |

Prevalence and Correlates of Disclosure of Positive Status

The 70 participants who had been aware of their HIV infection prior to enrolment provided data on 106 partnerships. They reported disclosing their HIV status in 73% of these partnerships (data not shown). Participant disclosure was associated with having injected longer than 9 years (aOR 6.04, 95% CI 1.53, 23.77; \( P = 0.010 \)) and with partners whom they perceived to be seropositive (aOR 45.12; 95% CI 2.79, 730.46; \( P = 0.007 \)) or IDUs (aOR 3.61; 95% CI 1.44, 9.06; \( P = 0.006 \)) (data not shown). No other participant characteristic (e.g., demographic, time since diagnosis, duration of drug use, incarceration history) or partnership characteristic (e.g., partnership type, partner’s age) was associated with disclosure behavior.

Association Between HIV Disclosure and Condom Use Among Participants Who Had Been Previously Aware of Their HIV Infection

Participants who were previously aware of their HIV infection used condoms at last intercourse in 52 (49%) of 106 partnerships (Table 3). Condoms were used in a minority of encounters with partners perceived to be positive (36%); their use was significantly more common with partners perceived to be negative (70%) but only slightly more likely with partners whose serostatus was perceived as unknown (48%). Disclosure was not independently associated with condom use. Instead, condom use differed only by perceived negative serostatus of partner when comparing them to partners perceived to be seropositive (aOR 3.85, 95% CI 1.45–10.21, \( P = 0.007 \); Table 3) or to all other partners (aOR 2.95, 95% CI 1.29–6.73 \( P < 0.05 \); data not shown). Perception of partner status was independently associated with condom use and was not confounded by any other
Table 3  Correlates of condom use at last intercourse among drug injectors who are aware of their HIV infection, St. Petersburg, Russia

|                  | Total Used condom No. (%) | uOR   | 95% CI          | P-value | aOR   | 95% CI          | P-value |
|------------------|---------------------------|-------|-----------------|---------|-------|-----------------|---------|
|                  |                            |       |                 |         |       |                 |         |
|                   | Total partnerships         | 106   | 52 (49)         | –       | –     | –               | –       |
| Disclosure of status by positive injector |                        |       |                 |         |       |                 |         |
| Yes              | 77                         | 34 (44) | 0.46 | 0.70–0.98 | 0.028  | –               | –       |
| No               | 29                         | 18 (62) | Ref            |         |       |                 |         |
| Gender           |                            |       |                 |         |       |                 |         |
| Male             | 67                         | 38 (57) | 2.09 | 0.81–5.41 | 0.129  | –               | –       |
| Female           | 39                         | 14 (36) | Ref            |         |       |                 |         |
| Age 28+          |                            |       |                 |         |       |                 |         |
| Yes              | 69                         | 32 (53) | 1.91 | 0.75–4.85 | 0.176  | –               | –       |
| No               | 47                         | 20 (43) | Ref            |         |       |                 |         |
| Known + 2 years  |                            |       |                 |         |       |                 |         |
| Yes              | 77                         | 39 (52) | 1.59 | 0.55–4.58 | 0.392  | –               | –       |
| No               | 26                         | 10 (38) | Ref            |         |       |                 |         |
| Ever in jail or prison |                        |       |                 |         |       |                 |         |
| Yes              | 50                         | 21 (42) | 0.58 | 0.23–1.45 | 0.241  | –               | –       |
| No               | 56                         | 31 (55) | Ref            |         |       |                 |         |
| Inject 9 years+  |                            |       |                 |         |       |                 |         |
| Yes              | 95                         | 49 (52) | 1.98 | 0.78–5.03 | 0.150  | –               | –       |
| No               | 11                         | 3 (27)  | Ref            |         |       |                 |         |
| IDU’s perception of partner’s serostatus |                        |       |                 |         |       |                 |         |
| Positive         | 39                         | 14 (36) | Ref            |         |       |                 |         |
| Negative         | 27                         | 19 (70) | 3.85 | 1.45–10.21 | 0.007  | 3.85           | 1.45–10.21 | 0.007 |
| Unknown          | 40                         | 19 (48) | 1.60 | 0.68–3.77 | 0.282  | 1.60           | 0.68–3.77 | 0.282 |
| Partner type     |                            |       |                 |         |       |                 |         |
| Main             | 41                         | 18 (44) | 0.58 | 0.30–1.11 | 0.098  | –               | –       |
| Other            | 51                         | 33 (65) | Ref            |         |       |                 |         |
| Partner injects  |                            |       |                 |         |       |                 |         |
| Yes              | 67                         | 29 (43) | 0.49 | 0.25–0.96 | 0.038  | –               | –       |
| No               | 33                         | 19 (58) | Ref            |         |       |                 |         |
|                   | With partners perceived to be seronegative or perceived unknown n_participants = 43 |       |                 |         |       |                 |         |
|                  |                            |       |                 |         |       |                 |         |
|                   | Total partnerships         | 67    | 19 (70)         | –       | –     | –               | –       |
| Disclosure of status by positive injector |                        |       |                 |         |       |                 |         |
| Yes              | 40                         | 20 (50) | 0.46 | 0.19–1.12 | 0.089  | 0.13           | 0.02–0.66 | 0.014 |
| No               | 27                         | 18 (67) | Ref            |         |       |                 |         |
| Gender           |                            |       |                 |         |       |                 |         |
| Male             | 46                         | 30 (65) | 3.10 | 0.85–11.28 | 0.086  | 23.61          | 1.59–349.97 | 0.022 |
| Female           | 21                         | 8 (38)  | Ref            |         |       |                 |         |
| Age 28+          |                            |       |                 |         |       |                 |         |
| Yes              | 35                         | 24 (69) | 2.52 | 0.79–8.03 | 0.040  | –               | –       |
| No               | 32                         | 14 (44) | Ref            |         |       |                 |         |
| Known + 2 years  |                            |       |                 |         |       |                 |         |
| Yes              | 49                         | 29 (49) | 2.41 | 0.60–9.71 | 0.217  | –               | –       |
| No               | 15                         | 6 (40)  | Ref            |         |       |                 |         |
| Ever in jail or prison |                        |       |                 |         |       |                 |         |
| Yes              | 31                         | 14 (45) | 0.44 | 0.14–1.42 | 0.173  | 0.02           | 0.0–0.30 | 0.005 |
| No               | 36                         | 24 (67) | Ref            |         |       |                 |         |
variable. In a model limited to partners perceived to be susceptible to HIV infection (i.e., perceived to be seronegative or of unknown serostatus), disclosure was independently and negatively associated with condom use (aOR 0.13, 95% CI 0.02–0.66; \( P = 0.014 \)). In the same model there was a positive and independent association between condom use and male gender of participant (aOR 23.61, 95% CI 1.59–349.97, \( P = 0.022 \)). In addition, condoms were more likely to be used with partner of perceived negative serostatus compared to partner of unknown serostatus (aOR 8.65, 95% CI 1.67–44.65, \( P = 0.010 \)).

**Potential for HIV Transmission in Unprotected Serodiscordant Partnerships**

We calculated the number of partnerships with the potential for HIV transmission, that is, unprotected sex partnerships between HIV-seropositive participants and partners perceived to be either seronegative or of unknown serostatus (\( n = 89 \)). The vast majority of these were unprotected vaginal sex, with only four encounters noting the occurrence of unprotected anal sex. Among these, partnerships in which participants had been unaware of who knew of their infection and seronegative partners but without disclosure, 6 (7%) between participants who knew of their infection and partners of unknown status but without disclosure, and 15 (17%) between participants who knew of their infection and had disclosed to the partner of unknown serostatus. Hence, there were only approximately 3% of unprotected sexual encounters in which disclosure of serostatus may have influenced the decision to use a condom. (Color figure online)
their HIV infection and understood their partner to be HIV-negative comprised 26% \( (n = 23) \), and partnerships in which participants had been aware of their infection but had not disclosed to their seronegative partners comprised 3% \( (n = 3; \text{ Fig. 2}) \).

**Discussion**

The study results indicate that mere awareness of one’s own HIV infection is not associated with condom use. Rather, among IDUs who were aware of their HIV infection, partner’s perceived serostatus was the strongest predictor of condom use at last intercourse. Compared to partnerships with partners perceived to be positive or of unknown serostatus, partnerships between IDUs who were aware of their infection and partners perceived to be seronegative were characterized by a relative lack of disclosure but more condom use. Consistent with other studies \[40, 53, 54\], we found that disclosure was not associated with increased condom use. Instead, disclosure to potentially negative partners was associated with less condom use.

Among participants who were aware of their HIV infection at time of last intercourse, disclosure was independently associated with (1) the perception that their sex partner was also HIV-positive, (2) the perception that their partner was also an IDU, and (3) the participant having injected for at least 9 years. The first finding is consistent with other studies’ findings that disclosure was less likely when partners’ serostatus was either seronegative or unknown \[28, 38–40\]. Disclosure to partners who were perceived to be fellow injectors may be related to the first finding and reflects the harsh reality of HIV in Russia: that anyone who injects drugs is likely to become infected. The fact that no other personal or partner characteristics or partnership type were associated with disclosure contrasts with studies of disclosure practices among US populations \[22, 26–33, 37, 43, 44, 55\]. Further research is warranted to confirm or refute our findings.

Among HIV-positive IDUs who were aware of their infection, it appears that the perception of partners as uninfected, more than the act of disclosure, was associated with condom use. Potential exposure of perceived negative partners was much more common among participants who had been unaware of their HIV infection at the time of last sexual contact. We applied the adjusted odds ratio between prior diagnosis of HIV infection and condom use with partners perceived to be negative given in Table 2 (aOR: 6.68, CI: 1.60–27.88) and the proportion of partnerships in which an undiagnosed participant with HIV infection had exposed potentially uninfected partners \( (0.26, \text{ binomial CI: } 0.17–0.36) \) to a standard formula for population attributable risk percent (PAR%).

\[ \text{PAR\%} = \frac{P_{\text{exposed}}(\text{RR} - 1)}{[1 + P_{\text{exposed}}(\text{RR} - 1)]} \]

This suggests that if half of the undiagnosed HIV-infected IDUs from the sampling frame were to learn of their HIV infection, the number of potentially uninfected partners being exposed by infected injectors would be reduced by 60% (CI 9–90%). Conversely, disclosure of HIV infection to potentially uninfected partners was associated with a somewhat lesser likelihood of using condoms. It is of interest that males who were aware of their HIV infection were significantly more likely than females to report having used a condom at time of last intercourse. This may be due to the fact that, compared to females, males can more easily opt to use a condom with minimal need for condom negotiation and no need for disclosure.

Limitations of the study included the inherent potential biases associated with self-reported data such as recall bias and social desirability. Due to the relatively small sample size, there was insufficient power to detect effect modification; under these conditions, stratification was considered to be the appropriate analytic approach. The cross-sectional nature of this study does not permit determination of causal associations. The survey questioned participants about whether they had asked their partners if they had been tested, but (1) did not follow up to ask whether partners had responded to the question or what those test results were and (2) whether discussions of serostatus happened before or after initiation of the sexual partnership. These methodological problems have been noted elsewhere \[27\]. We therefore cannot ascertain the degree to which a recent negative test is associated with protected sex with HIV-positive partners who are aware of their infection. Detailed data about the timing of disclosure relative to the onset of sexual relations should be collected in future studies. Further research is needed to understand the process by which individuals ascertain their partners’ HIV serostatus and to identify those factors which enter into condom use decisions. Finally, the study from which the data for this analysis were taken did not inquire whether HIV-diagnosed participants had been declined by potential sexual partners due to participants’ disclosure of HIV-positive status; while taking such scenarios into account would not change the proportion of partnerships in which condoms were used, it would impact the proportion of unprotected partnerships occurring post-disclosure.

Evidence from studies outside of Russia suggests that sexual risk behaviors may contribute more than injection risk behaviors to HIV transmission among IDUs when injection risks are reduced through educational, behavioral, or structural interventions \[56, 57\], but few interventions specifically target the reduction of sexual risk among this population \[58\]. Our experience working with this population in St. Petersburg indicates that condoms are readily
available and inexpensive at most convenience stores, pharmacies, and kiosks; they are also free at syringe exchanges and outreach programs. There are few published reports of condom use rates among IDUs or even within the general population of Russia, and even less is known about these rates among partner types (e.g., new, main, casual partners). However, there is some evidence that condom use rates are generally low, with 45% of injectors in one study reporting no condom use in the previous 6 months [59], another study noting consistent condom use for only 44% of a sample of Moscow youths [60], and 19–25% of respondents in a representative probability sample of Russian households reporting condom use at their last sexual encounter [61]. Elsewhere in the world the rates of unprotected sex for IDUs ranged from 28 to 77% [62–68].

Our findings suggest the need for interventions targeting increased condom use among Russian IDUs and that HIV testing—and provision of test results—should be encouraged among all members of social networks in which HIV disclosure, suggest that public health benefit (in terms of decreased sexual exposure to HIV by uninfected partners) may accrue from the scaling up HIV testing services and interventions that increase the likelihood of individuals receiving their test results.

Acknowledgments  Support for this work was provided by NIDA grants U01DA017377, William Zule, RTI International; U01DA017377, Martin Iguchi and Sandra Berry, RAND Corporation; U01DA017378, Lawrence Ouellet, University of Illinois, Chicago; U01DA017387, Robert Heimer and Andrei Kozlov, Yale University and the Biomedical Center; U01DA017394, Steve Shoptaw and Pamina Gorbach, University of California, Los Angeles. Data in St. Petersburg was collected by the Biomedical Center in collaboration with Yale University as part of SATH-CAP Study (“Doverie”).

Open Access  This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Elovich R, Drucker E. On drug treatment and social control: Russian narcology’s great leap backwards. Harm Reduct J. 2008;5:23.
2. UNAIDS. 2006 Report of the global AIDS epidemic. 2007. Available at www.unaids.org/en/HIV_data/2006GlobalReport/default.asp . Accessed 15 Nov 2007.
3. Goliusov AT, Dementyeva LA, Ladnaya NN, et al. Country progress report of the Russian federation on the implementation of the declaration of commitment on HIV/AIDS. Moscow, Federal Service for Surveillance of Consumer Rights Protection and Human Well-Being of the Russian Federation. 2009. Available at http://data.unaids.org/pub/Report/2008/russia_2008_country_progress_report_en.pdf. Accessed 21 May 2009.
4. UNAIDS. AIDS epidemic regional update, Eastern Europe and Central Asia. 2007. Available at http://data.unaids.org/pub/Report/2008/e1529_epibriefs_europe_casia_en.pdf. Accessed 21 May 2009.
5. Kozlov AP, HIV in Russia, Belorussia, and Ukraine. Russ J HIV/AIDS Relat Probl. 2000;4:11–4.
6. Krupitsky EM, Zvartau EE, Lioznov DA, et al. Co-morbidity of infectious and addictive diseases in St. Petersburg and the Leningrad Region. Russ Eur Addict Res. 2006;12(1):12–9.
7. Semaille C, Alix J, Downs AM, Hamers FF. The HIV infection in Europe: large East–West disparity. Euro Surveill. 2003;8(3):57–64.
8. United Nations Development Programme. HIV/AIDS in Eastern Europe and the commonwealth of independent states: reversing the epidemic. Facts and policy options. 2007. Available at http://europeandcis.undp/hiv/files/full_English.pdf. Accessed 15 Nov 2007.
9. Abdala N, Carney JM, Durante AJ, et al. Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St. Petersburg, Russia. Int J STD AIDS. 2003;14:697–703.
10. Niccolai LM, Shcherbakova IS, Tousova OV, Kozlov AP, Heimer R. The potential for bridging of HIV transmission in the Russian Federation: sex risk behaviors and HIV prevalence among drug users (DUs) and their non-DU sex partners. J Urban Health. 2009;86(Suppl 1):131–43.
11. Ostrovsky D. Injection drug use, HIV, hepatitis, and overdose in St. Petersburg. In: 8th International conference on AIDS, cancer, and related problems. St. Petersburg, Russia; 2000.
12. Ostrovsky DV. WHO drug injecting study in St. Petersburg, phase two. In: XIV International AIDS conference, Barcelona, Spain; 2002 [abstract WePeC6081].
13. Shabolots AV, Tousova OV, Hoffman IF, et al. HIV prevalence, sociodemographic, and behavioral correlates and recruitment methods among injection drug users in St. Petersburg, Russia. J Acquir Immune Defic Syndr. 2006;41:657–63.
14. Smol’skaya TT, Khodakevich LN, Kobylkoa InV, et al. An HIV prevalence study by means of sentinel epidemiological surveillance among injection narcotic abusers in Saint Petersburg [Russian]. Zh Mikrobiol Epidemiol Immunobiol. 2000;4:31–3.
15. Burchell AN, Calzavara LM, Orekhovskiy V, Ladnaya NN. Canada AIDS Russia project, Russian HIV response network. Characterization of an emerging heterosexual HIV epidemic in Russia. Sex Transm Dis. 2008;35:807–13.
16. Hamers FF, Downs AM. HIV in Central and Eastern Europe. Lancet. 2003;361:1035–44.
17. United Nations Programme on HIV/AIDS (UNAIDS). AIDS epidemic update: December 2003. 2009. Available at http://www.who.int/hiv/pub/epidemiology/epi2003/en/. Accessed 18 Mar 2009.
18. Centers of Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329–32.
19. Janssen RS, Valdisserri RO. HIV prevention in the United States: increasing emphasis on working with those living with HIV. J Acquir Immune Defic Syndr. 2004;37(Suppl 2):S119–21.
20. Simoni JM, Mason HR, Marks G, Ruiz MS, Richardson JL. Women living with HIV: sexual behaviors and counseling experiences. Women Health. 1995;23:17–26.
21. Sowell RL, Lowenstein A, Moneyham L, Demi A, Mizuno Y, Seals B. Resources, stigma, and patterns of disclosure in rural women with HIV infection. Public Health Nurs. 1997;14:302–12.
62. Anderson JE, Cheney R, Clatts M, Faruque S, Kipke M, Long A, et al. HIV risk behavior, street outreach, and condom use in eight high-risk populations. AIDS Educ Prev. 1996;8:191–204.
63. Belanger D, Godin G, Alary M, Bernard P-M. Factors explaining the intention to use condom among injecting drug users participating in a needle-exchange program. J Appl Soc Psychol. 2002;32:1047–63.
64. Bogart LM, Kral AH, Scott A, Anderson R, Flynn N, Gilbert ML, et al. Condom attitudes and behaviors among injection drug users participating in California syringe exchange programs. AIDS Behav. 2005;9:423–32.
65. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. 2000;58:219–26.
66. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr. 2002;31:422–31.
67. Vanichseni S, Des Jarlais DC, Choopanya K, Friedmann P, Wenston J, Sonchai W, et al. Condom use with primary partners among injecting drug users in Bangkok, Thailand and New York City, United States. AIDS. 1993;7:887–91.
68. White D, Phillips K, Mulleady G, Cupitt C. Sexual issues and condom use among injecting drug users. AIDS Care. 1993;5:427–37.